By Hugo Francisco de Souza A novel CAR-T cell approach targets amyloid plaques in preclinical Alzheimer models, raising the ...

Chimeric antigen receptor (CAR) T-cell therapies have transformed cancer and autoimmune disease treatment. Modified CAR proteins equip T cells with the ability to identify and eliminate cancer cells ...

CAR T cell therapies are effective across a range of leukaemias and lymphomas, but have failed to yield consistent, durable responses in solid tumours. To help address this issue, strategies to boost ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma. A next-generation "armored" CAR T cell therapy ...

Weizmann and Washington U. scientists harness CAR T-cell therapy to fight brain tissue inflammation in mice, potentially ...

Traits of noncancerous cells in diffuse large B-cell lymphoma (DLBCL) tumors appear to offer insight into which patients will benefit the most from chimeric antigen receptor (CAR) T-cell therapy, ...

CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Identifying tumor-selective antigens like CDH17, GD2, and ...

Chimeric antigen receptor (CAR) T cell therapy improves the detection and elimination of cancerous cells by genetically editing a patient’s immune cells to target tumor-associated antigens. This type ...

CAR-T is a powerful tool which is still evolving. Here we highlight what is new in CAR-T cell therapy Cancer cells often play hide-and-seek with the immune system in an attempt to evade catastrophic ...

CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has revolutionized how physicians treat cancer, especially blood cancers. “These patients can be cured ...